BICR indicates blinded independent central review. Two patients were included based on investigator’s assessment of papillary renal cell carcinoma subtype, which did not receive positive confirmation on ad hoc revision of histopathologic analysis, as per protocol. These patients remained in the analysis set (1 patient in each group).
BICR indicates blinded independent central review; HR, hazard ratio; NC, not calculated; OS, overall survival; PFS, progression-free survival.
BICR indicates blinded independent central review.
aNine patients (savolitinib n = 6; sunitinib n = 3) were not included in the target lesion size plot: no target lesions present at baseline that were selected as target lesions for the purpose of BICR assessment (n = 7: savolitinib n = 5, sunitinib n = 2); no postbaseline target lesion assessment captured (savolitinib n = 1; sunitinib n = 1).
eTable 1. Extent of disease at baseline
eTable 2. Progression-Free Survival And Overall Survival Outcomes Stratified By Prognostic Groups
eTable 3. Safety Outcomes
eTable 4. Most Common Adverse Events Independent of Causality, Reported in Over 10% of Patients in Either Treatment
eTable 5. Post-Discontinuation Disease-Related Anticancer Therapy
Statistical Analysis Plan
Data Sharing Statement
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Choueiri TK, Heng DYC, Lee JL, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online May 29, 2020. doi:10.1001/jamaoncol.2020.2218
Is savolitinib monotherapy more effective than sunitinib monotherapy on progression-free survival (PFS) in patients with MET-driven, unresectable and locally advanced, or metastatic papillary renal cell carcinoma (PRCC)?
In this phase 3, open-label, randomized clinical multicenter study including 60 patients with MET-driven PRCC, the primary end point was PFS. Although study enrollment was closed early, PFS was not statistically different for patient who received savolitinib or sunitinib, and the safety profile was superior with savolitinib.
Further investigation of savolitinib as a treatment option for MET-driven PRCC is warranted.
Papillary renal cell carcinoma (PRCC) is the most common type of non–clear cell RCC. Because some cases of PRCC are MET-driven, MET inhibition could be a targeted treatment approach. In previous studies, savolitinib (AZD6094, HMPL-504, volitinib), a highly selective MET-tyrosine kinase inhibitor, demonstrated antitumor activity in this patient group.
To determine whether savolitinib is a better treatment option for this patient population, vs standard of care, sunitinib.
Design, Setting, and Participants
The SAVOIR phase 3, open-label, randomized clinical trial was a multicenter study carried out in 32 centers in 7 countries between July 2017 and the data cutoff in August 2019. Overall, 360 to 450 patients were to be screened, to randomize approximately 180 patients. Patients were adults with MET-driven (centrally confirmed), metastatic PRCC, with 1 or more measurable lesions. Exclusion criteria included prior receipt of sunitinib or MET inhibitor treatment. Overall, 254 patients were screened.
Patients received 600 mg of savolitinib orally once daily (qd), or 50 mg of sunitinib orally qd for 4 weeks, followed by 2 weeks without treatment.
Main Outcomes and Measures
The primary end point was progression-free survival (PFS, assessed by investigator and confirmed by blinded independent central review). Secondary end points included overall survival (OS), objective response rate (ORR), duration of response, and safety/tolerability.
At data cutoff, 60 patients were randomized (savolitinib n = 33; sunitinib n = 27); most patients had chromosome 7 gain (savolitinib, 30 [91%]; sunitinib, 26 [96%]) and no prior therapy (savolitinib, 28 [85%]; sunitinib, 25 [93%]). For savolitinib and sunitinib, 4 (12%) and 10 (37%) patients were women, and the median (range) age was 60 (23-78) and 65 (31-77) years, respectively. Following availability of external data on PFS with sunitinib in patients with MET-driven disease, study enrollment was closed. Progression-free survival, OS, and ORR were numerically greater with savolitinib vs sunitinib. Median PFS was not statistically different between the 2 groups: 7.0 months (95% CI, 2.8-not calculated) for savolitinib and 5.6 months (95% CI, 4.1-6.9) for sunitinib (hazard ratio [HR], 0.71; 95% CI, 0.37-1.36; P = .31). For savolitinib and sunitinib respectively, grade 3 or higher adverse events (AEs) were reported in 14 (42%) and 22 (81%) of patients and AE-related dose modifications in 10 (30%) and 20 (74%). After discontinuation, 12 (36%) and 5 (19%) of patients on savolitinib and sunitinib respectively, received subsequent anticancer therapy.
Conclusions and Relevance
Although patient numbers and follow-up were limited, savolitinib demonstrated encouraging efficacy vs sunitinib, with fewer grade 3 or higher AEs and dose modifications. Further investigation of savolitinib as a treatment option for MET-driven PRCC is warranted.
ClinicalTrials.gov Identifier: NCT03091192
Kidney cancer is among the 10 most common cancers worldwide and is expected to account for 73 750 new cases in the US alone in 2020.1 Over 90% of kidney tumors are renal cell carcinoma (RCC), which consists of several heterogeneous subtypes with highly variable clinical courses and outcomes.2,3 Clear cell RCC (ccRCC) accounts for approximately 75% of all RCC and more than 80% of metastatic RCC; therefore, clear cell is the dominant histologic steering development of systemic therapies for all RCC subtypes.3-5 Over the past 2 decades, critical genomic findings such as the early loss of the VHL tumor suppressor gene in ccRCC paved the way for development of targeted therapies, which have improved outcomes in patients with ccRCC.6,7 Conversely, non-ccRCC (nccRCC) subtypes vary widely in their cytologic and molecular abnormalities.5 When treated with approved therapies for ccRCC, outcomes in nccRCC are demonstrably worse.3,4,8 This is presently the case for the dominant nccRCC subtype papillary RCC (PRCC), which accounts for approximately 15% of all RCC.9-11
Papillary RCC is histologically subclassified into the more indolent type-1 PRCC and aggressive type-2 PRCC; however, these classifications have poor consensus among pathologists, and molecular/genetic analyses appear to have greater utility.9,10,12 Type-1 PRCC has been associated with amplification of the MET gene on chromosome 7q31, which is thought to drive disease.9,10 Hereditary MET variations are rare but have been characterized and found to manifest as multifocal, bilateral type-1 PRCC tumors.13 The MET gene encodes a receptor tyrosine kinase that in the tumor setting, drives proliferation, angiogenesis, and metastatic seeding.14 Aberrant MET activation may occur through genetic alterations, including: gain of chromosome 7; focal amplification of either MET or its ligand hepatocyte growth factor (HGF); or hyperactivating MET kinase domain variations.9,15 The MET gene has been found to be a major chromosome-level alteration in 81% of type-1 PRCC but also 46% of type-2 PRCC, whereas less common somatic variations in the kinase domain occur in 13% of all PRCC.9,16,17
Savolitinib (AZD6094, HMPL-504, volitinib) is a potent and selective MET inhibitor under investigation in several malignant diseases. Savolitinib was advanced for clinical development based on promising single-agent activity in 2 patient-derived xenograft murine models of PRCC.18 In the first-in-human phase 1 study of savolitinib in 48 patients with advanced solid tumors, 3 patients experienced a partial response (PR).19 All 3 had PRCC and were retrospectively determined to have MET-driven disease. In a phase 2 study of savolitinib in 109 patients with PRCC, 8 of 44 patients (18%) who were determined to have MET-driven disease showed an objective response (all PR).20 No patients with MET-independent PRCC responded. Results from this study justified the investigation of savolitinib in a randomized clinical trial of MET-driven, locally advanced, or metastatic PRCC.20
Sunitinib, is an oral multikinase inhibitor approved for the treatment of advanced RCC. Sunitinib is considered the standard-of-care treatment option in PRCC.21-23 The activity of sunitinib in PRCC was previously reported in a single-arm study in the first-line setting: median progression-free survival (PFS), was 6.6 months (95% CI, 2.8-14.8) in type-1 PRCC and 5.5 (95% CI, 3.8-7.1) in type 2. Median overall survival (OS) was 17.8 (95% CI, 5.7-26.1) months and 12.4 (95% CI, 8.2-14.3) months in type 1 and type 2, respectively.24 Despite limited responses to vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) like sunitinib observed in these phase 2 studies, there are no proven treatments approved specifically for PRCC.
Here, we report the results of SAVOIR (NCT03091192), a phase 3, open-label, randomized clinical multicenter study to assess the efficacy and safety of savolitinib vs sunitinib in patients with MET-driven, unresectable, and locally advanced or metastatic PRCC.
The study included adult patients (≥18 years) who had MET-driven, unresectable, and locally advanced/metastatic histologically confirmed PRCC.25 An MET-driven tumor was defined as presence of any of the following molecular alterations, in the absence of co-occurring FH or VHL variations: chromosome 7 gain, MET amplification, MET kinase domain variations, or HGF amplification.26
The trial protocol is available in Supplement 1. For inclusion and exclusion criteria, see the eMethods in Supplement 2.
In this sponsor-blinded study, patients were randomized in a 1:1 ratio to receive treatment with 600 mg of oral savolitinib (or 400 mg if <50 kg) once daily, given continuously, or 50 mg of oral sunitinib once daily in 6-week cycles of 4 weeks of treatment followed by 2 weeks without treatment. Patients were stratified based on the International mRCC Database Consortium risk-group criteria27 using the number of predefined risk factors to assign patients into favorable, intermediate, or poor prognostic groups, as well as whether they were treatment-naïve or previously treated with or without a VEGF-TKI. The investigational agent savolitinib was provided by the trial sponsor, AstraZeneca. The comparator sunitinib was purchased from Pfizer, Inc.
Efficacy was assessed by imaging every 6 weeks (computed tomographic [CT] or magnetic resonance imaging [MRI]), corresponding to the start of each treatment cycle, and then every 12 weeks after the first year, until disease progression as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). All scan results were read by blinded independent central review (BICR) after notification of progressive disease (PD) by the investigator.
The study was approved by the independent institutional review board associated with each study center. The study was performed in accordance with the Declaration of Helsinki and was consistent with International Conference on Harmonisation/Good Clinical Practice guidelines, applicable regulatory requirements, and the AstraZeneca policy on bioethics and human biologic samples. Written informed consent was obtained from all participants.
The primary end point was duration of PFS, defined as the interval between dates of randomization and first documentation of disease progression (assessed by investigator using RECIST 1.1 criteria and confirmed by BICR) or death, regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to progression. Secondary end points included OS, disease control rate (BICR), objective response rate (ORR), duration of response (DOR), and best percentage change in tumor size (all assessed by BICR using RECIST 1.1 criteria). For health-related quality of life methods and results, see eMethods and eResults in Supplement 2.
Approximately 360 to 450 patients were planned to be screened, to randomize approximately 180 patients; however, recruitment to the study was closed prematurely on November 22, 2018. Further statistical methods are in eMethods in Supplement 2. Statistical calculations were performed with SAS statistical software (version 9.4. SAS Institute, Inc). Analysis of the data occurred between September 13, 2019 and October 29, 2019. The statistical analysis plan is available in Supplement 3.
From July 2017 to November 2018, 254 patients were enrolled for screening; of these, a total of 60 (female n = 14, 23%) were randomized to either savolitinib (33 patients) or sunitinib (27 patients) treatment (Figure 1). For savolitinib and sunitinib, 4 (12%) and 10 (37%) patients were women, and the median (range) age was 60 (23-78) and 65 (31-77) years, respectively. The treatment groups were generally well-balanced (Table 1) (eTable 1 in Supplement 2). All patients randomized to savolitinib received 600 mg of savolitinib once daily. As of data cutoff, 23 (38%) patients were in ongoing treatment: 14 (42%) in the savolitinib group and 9 (33%) in the sunitinib group. Race and ethnicity were recorded by the investigator during screening to monitor the distribution of race and ethnicity across treatment groups, and to allow identification of race- or ethnicity-related treatment effects.
The low number of randomized patients was owing to this trial being halted prematurely because a concurrent retrospective molecular epidemiology study on the outcomes of patients with MET-driven PRCC on sunitinib suggested that MET-driven status did not appear to be a negative predictive factor for treatment outcomes.28 It was therefore concluded that the trial would be unlikely to detect a difference in efficacy between the treatment groups, and a decision was made to terminate recruitment.
For the primary end point of PFS, there were 17 of 33 patients (52%) with progression events in the savolitinib group vs 20 of 27 (74%) in the sunitinib group (hazard ratio [HR], 0.71; 95% CI, 0.4-1.4) (Figure 2A), which was not statistically significant (P = .31). The median PFS was 7.0 months (95% CI, 2.8 to not calculated [NC]) in the savolitinib group and 5.6 months (95% CI, 4.1-6.9) in the sunitinib group.
Nine patients (27%) from the savolitinib group died, vs 13 (48%) with sunitinib. The median OS was not reached for the savolitinib group (95% CI, 11.9-NC) and 13.2 months (95% CI, 7.6-NC) for the sunitinib group. The observed OS HR was 0.51 (95% CI, 0.2-1.2; P = .11) (Figure 2B). The ORR showed 9 of 33 (27%) patients (95% CI, 13.3-45.5) in the savolitinib group had a response, compared with 2 of 27 (7%) patients (95% CI, 0.9-24.3) in the sunitinib group; all responses were partial. Efficacy outcomes stratified by prognostic groups can be found in eTable 2 in Supplement 2.
As of the data cutoff of August 19, 2019, no responding patients in the savolitinib group had disease progression, compared with 1 of 2 responding patients in the sunitinib group. It was not possible to calculate median DOR from the data because there were too few events; 3 responders treated with savolitinib were followed for more than 6 months after onset of response. For disease control rate, at the 6-month time point, there were 16 of 33 (48%) and 10 of 27 (37%) patients in the savolitinib and sunitinib groups, respectively, and at the 12-month time point there were 10 of 33 (30%) and 6 of 27 (22%) patients in the savolitinib and sunitinib groups, respectively. More patients in the savolitinib group showed a decrease in target lesion size, particularly those with PR to therapy (Figure 3).
All time-to-events analyses should be interpreted with caution because of the limited number of patients enrolled and the limited follow-up due to the study’s premature termination.
Adverse events (AEs) of any cause occurred in 30 of 33 (91%) of the savolitinib group and 100% of the sunitinib group (eTable 3 in Supplement 2). Twenty-two patients died during the study; with 3 deaths attributed to AEs, all in the sunitinib group. In the savolitinib group, AEs led to discontinuation in 6 (18%) patients, vs 5 (19%) in the sunitinib group. Exposure was similar between groups: median total treatment duration of 7.6 (lower-upper quartile, 1.8-9.3) months in the savolitinib group vs 5.7 (lower-upper quartile, 3.7-12.0) months in the sunitinib group.
The most common AEs with savolitinib were peripheral edema (11 [33%]), increased creatinine levels (9 [27%]), aspartate aminotransferase increased (8 [24%]), and alanine aminotransferase increased (8 [24%]); with sunitinib, the most common AEs were anemia (12 [44%]), nausea (9 [33%]), decreased appetite (8 [30%]), thrombocytopenia (7 [26%]), and palmar-plantar erythrodysesthesia syndrome (7 [26%]) (Table 2) (eTable 4 in Supplement 2). Of note, thrombocytopenia and/or neutropenia was seen in 10 (37%) patients who received sunitinib vs no patients who received savolitinib. There was a similar proportion of serious AEs (SAEs) reported in both treatment groups: 8 [24%] vs 8 [30%] for savolitinib and sunitinib, respectively, with none reported by more than 1 patient and no notable differences between the groups.
Of patients who discontinued treatment (19 [58%] vs 18 [67%] for savolitinib and sunitinib, respectively), the most common reason in both groups was disease progression, whether or not this was confirmed by BICR. There were fewer patients with a dose interruption in the savolitinib arm (9 [27%]) than in the sunitinib arm (15 [56%]). Most cases of dose interruption across both treatments were due to AEs: 8 (24%) and 15 (52%) in the savolitinib and sunitinib arms, respectively. After discontinuation, 12 patients (36%) taking savolitinib and 5 patients (19%) taking sunitinib received subsequent anticancer therapy (eTable 5 in Supplement 2).
There remains an urgent unmet need for effective therapies in PRCC. Herein we have shown that, in a limited number of patients, savolitinib was associated with a superior safety and tolerability profile and numerically improved efficacy compared with sunitinib. However, premature termination of the study and the limited number of patients randomized is a key limitation and makes definitive conclusions on safety and efficacy difficult to draw.
In this study, the primary end point was PFS. There was no statistically significant difference between the PFS times for the 2 treatments, though PFS rates were numerically higher at months 6, 9, and 12 in the savolitinib group than in the sunitinib group, hence some separation seen in the Kaplan-Meier curves, beyond approximately 6 months. However, it should be noted that the number of patients at risk at these points was low. In addition, savolitinib was associated with a numerically better survival rate (with early separation of the Kaplan-Meier curves), a higher ORR, and a higher proportion of disease control at both the 6- and 12-month time points. Sunitinib performed in line with previous prospective studies of patients with PRCC unselected for MET status.21,22,24,28
Though the proportion of patients reporting an AE was similar in both treatment regimens, more patients in the sunitinib group reported AEs that were possibly treatment-related, as well as AEs that were grade 3 or higher. Similarly, around a quarter of patients receiving savolitinib, vs over half of patients on sunitinib, had a treatment interruption. In both cohorts, most interruptions were due to AEs; however, the proportion was lower in the savolitinib group than the sunitinib group. Lastly, it is noteworthy that more patients discontinued sunitinib than savolitinib and more patients from the savolitinib arm received a subsequent therapy, vs the sunitinib arm. This is possibly owing to savolitinib having a better tolerability profile than sunitinib, so patients were more likely to be able to tolerate further treatment. Treatment exposure was similar between the 2 groups. However, as with the efficacy outcomes, the low patient numbers must be taken into consideration when comparing these findings. In addition, the treatment regimen should be considered: here, sunitinib was received once daily for 4 weeks, followed by 2 weeks without treatment. Elsewhere, a schedule of 2 weeks of treatment, followed by 1 week without, has been associated with improved safety outcomes.29
When SAVOIR was conceived, there was a dearth of data on the natural disease history and/or epidemiology of MET-driven PRCC. A crucial assumption for this study was that MET-driven status in PRCC is a negative predictor for treatment outcomes on sunitinib.30,31 The molecular epidemiology study was initiated for this reason. The analysis for that study indicated that the PFS of patients with PRCC treated with sunitinib was longer than anticipated in the SAVOIR power calculation. The SAVOIR protocol specified that a new power calculation should be performed when the results of molecular epidemiology study became available. With the longer PFS, a much larger study would be needed, so it was decided to stop recruitment for SAVOIR. In addition, because the molecular epidemiology study suggested a trend toward more favorable sunitinib treatment outcomes in MET-driven vs MET-independent metastatic PRCC, it was decided that the SAVOIR study would not benefit from a reassessment of study size given the expected similarity in efficacy between the 2 treatment groups.20,40 Due to the study’s early termination, the percentage of screened patients who were randomized was lower than the planned target of 40%, which was roughly the incidence of MET-driven disease from the phase 2 study.20 In addition, another key difference between SAVOIR and the phase 2 study was in the definition of MET-driven disease, as here, patients with VHL and FH variations were excluded.
Previous studies have tested MET-targeted therapy in patients with PRCC: the first prospective trial to do so was the phase 2 open-label biomarker study of the oral multikinase inhibitor foretinib in 74 patients.32 Though the trial failed to reach its response rate end point of 25%, when patients were stratified by MET status, 5 of 10 patients (50%) with a germline MET variation experienced a response compared with 5 of 57 (9%) without a germline MET variation (all PR). Somatic MET variations (1/5; 20%), MET amplification (0/2; 0%), and chromosome 7 gain (1/18; 5%) did not correlate with activity. Crizotinib, another oral multikinase inhibitor, was employed in a phase 2, open-label, biomarker study testing for efficacy in patients with MET-driven type-1 PRCC.33 The investigators defined MET driven as a variation in exons 16 to 19 of the MET gene, and because only patients with centrally confirmed diagnoses of type-1 PRCC were eligible, only 4 MET-driven patients were treated, of whom 2 experienced PR (50%). Importantly, the study also raised the question of the role of MET amplification in a post hoc analysis. From a safety standpoint, crizotinib’s most frequent AE was edema (47.8%). Importantly, both foretinib and crizotinib have significant polypharmacology with other kinases in addition to MET.34,35
Results of earlier studies in MET-driven PRCC raise the question of optimal study population for targeting MET. Response rates to MET-targeted therapy in patients with MET variations were higher than those with chromosome 7 copy number alterations or MET amplifications.20 However, these patients are rare in an already rare subgroup of MET-driven PRCC: only 5 (8%) patients in this study had an MET variation, whereas most (56, 93%) had gain of chromosome 7. It is therefore plausible that a narrower definition of MET-driven status would identify patients who experience significant benefit with savolitinib therapy; however, this raises new difficulties in trial design and recruitment and would only benefit a minority of patients.
In the SWOG S1500, multiarm, phase 2 trial originally comparing cabozantinib, crizotinib, savolitinib, and sunitinib in patients with metastatic PRCC (not selected for MET status), the savolitinib arm was closed early and is yet to report.36 A phase 1/2 study of savolitinib in combination with the anti–PD-L1 antibody, durvalumab, in patients with metastatic PRCC showed 27% ORR (n = 41)37; importantly, MET-driven status (defined by immunohistochemical analysis) was not associated with a significantly higher ORR (40%).38 However, given the involvement of dysregulated pathways beyond the MET pathway and the growing importance of combination therapies in metastatic RCC,39 perhaps savolitinib could be investigated as part of an effective treatment strategy in this patient population: using an increased number of patients, MET-confirmation with next-generation sequencing, and a longer follow-up period to better assess the combination.
It should be noted that using MET as a biomarker remains challenging because different testing methods detect different subsets of patients with MET-based disease, and it is therefore unclear which biomarker is the best predictor for sensitivity to MET-targeted therapies.25
Premature termination of the study and the limited number of patients randomized are key limitations of this study and make definitive conclusions on safety and efficacy difficult to draw.
Overall, in SAVOIR, early termination of recruitment precludes definitive conclusions from being drawn owing to the small data set. Though none of the study end points reached significance, the limited efficacy data favored savolitinib over sunitinib in this study, and savolitinib showed a superior safety and tolerability profile. Though the retrospective molecular epidemiology study suggested that MET-driven status did not appear to be a negative predictive factor for treatment outcomes, our clinical findings suggest differently and thus, given the potential to improve treatment for MET-driven PRCC with savolitinib, a new study of the same population is being considered at this time.
Corresponding Author: Toni K. Choueiri, MD, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215 (firstname.lastname@example.org).
Accepted for Publication: May 2, 2020.
Published Online: May 29, 2020. doi:10.1001/jamaoncol.2020.2218
Correction: This article was corrected on June 25, 2020, to acknowledge a change in license type from standard to open access.
Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2020 Choueiri TK et al. JAMA Oncology.
Author Contributions: Dr Choueiri had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Choueiri, Lee, Ottesen, Frigault, Albiges.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Verheijen, Szijgyarto.
Administrative, technical, or material support: Choueiri, Lee, Cancel, Verheijen, Mellemgaard, Frigault, L'Hernault.
Supervision: Choueiri, Heng, Lee, Verheijen, Mellemgaard, Ottesen, Albiges.
Conflict of Interest Disclosures: Dr Choueiri reports receiving research support (institutional and personal) from AstraZeneca, Alexion, Bayer, Bristol Myers-Squibb/ER Squibb and Sons LLC, Cerulean, Eisai, Foundation Medicine Inc, Exelixis, Ipsen, Tracon, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Analysis Group, Sanofi/Aventis, and Takeda; honoraria from AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol-Myers Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc, Exelixis, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, Analysis Group, NCCN, Michael J. Hennessy (MJH) Associates, Inc (Healthcare Communications Company with several brands such as OncLive, PeerView, and PER), Research to Practice, L-path, Kidney Cancer Journal, Clinical Care Options, Platform Q, Navinata Healthcare, Harborside Press, American Society of Medical Oncology, NEJM, Lancet Oncology, Heron Therapeutics, and Lilly; has had a consulting or advisory role for AstraZeneca, Alexion, Sanofi/Aventis, Bayer, Bristol-Myers Squibb/ER Squibb and sons LLC, Cerulean, Eisai, Foundation Medicine Inc, Exelixis, Genentech, Heron Therapeutics, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group, Pionyr, and Tempest; owns stock in Pionyr and Tempest; and has received travel, accommodations, and expenses in relation to consulting, advisory roles, or honoraria. Dr Heng reports consultancies with and honoraria from AstraZeneca, Pfizer, Novartis, BMS, Ipsen, Exelixis, and Merck. Dr Lee reports grants, personal fees, and other from Pfizer Korea and Ipsen Korea; personal fees and other from Janssen, Sanofi Aventis, Astellas Korea, and BMS Korea; and personal fees from Novartis Korea, outside the submitted work. Dr Verheijen is an employee of AstraZeneca and owns shares in AstraZeneca and Aduro Biotech. Dr Mellemgaard is an employee of AstraZeneca. Dr Ottesen is an employee of and owns shares in AstraZeneca. Dr Frigault is an employee, patent holder, and stock owner of AstraZeneca. Dr L’Hernault is an employee of and owns shares in AstraZeneca. Dr Szijgyarto is an employee of and owns shares in AstraZeneca, and reports receiving a long-term incentive as part of rewarding performance. Dr Signoretti reports receiving commercial research grants from Bristol-Myers Squibb, AstraZeneca, and Exelixis; is a consultant/advisory board member for Merck, AstraZeneca, Bristol-Myers Squibb, AACR, and NCI; and receives royalties from Biogenex. Dr Albiges reports research funding from Bristol-Myers Squibb; consultancy/advisory roles with Bristol-Myers Squibb, Novartis, Amgen, Ipsen, Roche, Pfizer, Merck, MSD, and AstraZeneca; and travel/accommodation expenses from Bristol-Myers Squibb and MSD. No other disclosures were reported.
Funding/Support: Funding support provided by AstraZeneca. The study (NCT03091192) was funded by AstraZeneca, Cambridge, UK the manufacturer of savolitinib.
Role of the Funder/Sponsor: AstraZeneca played a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication and as such are included in the author list and acknowledgments.
Meeting Presentation: This article was presented during the 2020 ASCO Virtual Scientific Program; May 29-31, 2020.
Additional Contributions: Thanks to all the patients and their families. The authors acknowledge Kevin Pels, PhD, of Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, for medical writing support and Bernadette Tynan, MSc, of Ashfield Healthcare Communications, Macclesfield, UK, for technical editing assistance that was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publications Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).
Data Sharing Statement: See Supplement 4.
Create a personal account or sign in to: